
BDTX P/E Ratio
P/E Ratio as of Jul 11, 2025: 46.52
Average40.24
Median40.19
Minimum36.79
Maximum46.52
46.52
Past Month+8.11 (21.11%)
The P/E ratio for BDTX is 46.52 as of Jul 11, 2025. This represents a increase of 877.31% compared to its 12-month average P/E ratio of 4.76. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Black Diamond Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Black Diamond Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Black Diamond Therapeutics to industry peers.
Black Diamond Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Black Diamond Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Black Diamond Therapeutics to industry peers.
BDTX P/E Ratio Insights
See Black Diamond Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares
BDTX P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jul 1, 2025 | $2.48 | 40.19 |
Jun 2, 2025 | $2.37 | 38.41 |
May 1, 2025 | $1.70 | -1.34 |
Apr 1, 2025 | $1.49 | -1.17 |
Mar 3, 2025 | $1.91 | -1.40 |
Feb 3, 2025 | $2.45 | -1.80 |
Jan 2, 2025 | $2.14 | -1.57 |
BDTX End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | 46.52 | -3,063.06% |
2024 | -1.57 | +18.94% |
2023 | -1.32 | +94.12% |
2022 | -0.68 | -55.84% |
2021 | -1.54 | -91.01% |
2020 | -17.13 | — |
FAQs About Black Diamond Therapeutics (BDTX) P/E ratio
The latest P/E ratio of BDTX is 46.52, as of Jul 11, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Black Diamond Therapeutics’s last 12-month average P/E ratio is 4.76, compared to its current P/E ratio of 46.52. This reflects a increase of 877.31%.
Black Diamond Therapeutics’s current P/E ratio of 46.52 is higher than its last 12-month average P/E of 4.76. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Black Diamond Therapeutics’s average P/E ratio over the last 3 years is 0.57. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Black Diamond Therapeutics’s average P/E ratio over the last 5 years is -3.07. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.